Featured Resources
-
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Case study
Target Classes | ION Channels
TRP Channels
Access the Assays You Need
Sygnature Discovery’s comprehensive TRP channel selectivity panel comprises 21 human TRP channels spanning TRPA, TRPC, TRPM, TRPML and TRPV families as well as an additional array of species orthologs. Choose from our standard panel or take advantage of ou r flexible service enabling design of your own custom TRP selectivity panel.
Flexible Assay Formats
Sygnature Discovery’s flexible assay formats offer an extensive range of optimized TRP channel assays, providing accurate, reliable data without the challenges of in-house development. Leveraging this adaptability, our scientists support rapid hit identification and investigation into TRP channel cross -reactivity, enabling efficient exploration and identification of novel, target-selective compounds. This flexible approach empowers drug discovery efforts with tailored solutions designed to meet unique research needs and accelerate project timelines.
TRP Channel Electrophysiology
Figure 1: Representative TRPA1 current traces before (grey line) and during the presence of increasing concentrations of the blocker A967079 (blue lines). A 300 ms ramp protocol from -60 mV to +60 mV, from a holding potential of +0 mV and repeated every 30 seconds is used to monitor the TRPA1 current.
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Sitryx: Empowering New Ideas
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Corcept Therapeutics: Integrated Drug Discovery Collaboration
Corcept Therapeutics, located in Menlo Park, CA, is a leader in the discovery and development of drugs that regulate the effects of cortisol.
CellCentric Lead Optimisation Campaign – CCS1477
CellCentric are developing new treatments for cancer based on their understanding of epigenetics.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Hit Identification to 3 Compounds in the Clinic and 6 Development Candidates
UK-based small molecule drug discovery company
Focus on identifying novel treatments of inflammatory respiratory diseases, such as COPD
Explore Our Approach to Ion Channel Drug Discovery
Ebook
Ion channels are among the most complex and commercially important targets in drug discovery. This free ebook brings together over 20 years of Sygnature Discovery’s experience supporting even the most challenging program.
Explore how we combine custom cell-based assay development, specialist electrophysiology platforms, and fully integrated discovery support – including DMPK, in vivo pharmacology and protein sciences – to help you progress from hit to lead with confidence. Read More
Related Capabilities
We bring together a dynamic blend of new talent and experiences pharmaceutical industry experts from around the world, delivering excellence across each stage of discovery.
Ion channels
Comprehensive ion channel assays and bespoke cell lines deliver high-fidelity screening and safety insights, accelerating hit-to-lead and optimization.
Cell line generation
Custom stable cell lines with robust expression and assay reproducibility, streamlined design and validation for confident drug discovery workflows.
Electrophysiology
Precise ion channel and transporter insights through tailored electrophysiology studies supporting target validation, hit identification, and lead optimization decisions.
High throughput screening
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.